Dr Stuart Curbishley

SC1crop_small
Dr Stuart Curbishley is a liver immunologist who is closely involved in vaccination approaches to target hepatocellular carcinoma, and cell therapy approaches to limit chronic inflammation.
Position:

NIHR Research Fellow, Universi, University of Birmingham Medical School, NIHR Biomedical Research Unit and Centre for Liver Research, College of Medical Sciences and Dentistry, University of Birmingham.

Email: s.m.curbishley@bham.ac.uk

LinkedIn profile

Background and Research focus

Following a BSc in Biomedical Science and an MPhil in Immunology and Oncology, Stuart studied for a PhD in the laboratory of Professor David Adams, completing these studies in 2005.  His research focused on understanding leukocyte homing to the inflamed liver.  Since then, he has become a key member of the NIHR Liver Biomedical Research Unit and the Centre for Liver Research (CLR).  Based in the Institute for Biomedical Research, his research interests centre around the recruitment and role of dendritic cells (DC) and macrophages in immune regulation in the liver, with particular emphasis on the use of DC in immunotherapy strategies targeting liver cancer.  He has set up and manages a GCLP laboratory within the CLR running immune endpoint analyses for early phase clinical trials, transferring laboratory protocols to GMP compliant processes and developing clinical data sets for trial design studies.  He has played a leading role in development of ImmunoTACE, an NIHR-funded randomised Phase II clinical trial led by Professor David Adams testing the efficacy of vaccination with DC pulsed with liver cancer antigens in patients with Hepatocellular Carcinoma. As part of this work, Stuart has played an important role in developing the Advanced Therapies Facility, which is embedded within the NIHR/Wellcome Trust Clinical Research Facility  and incorporates a GCLP laboratory and GMP cell therapy suite, for use in cellular immunotherapy studies.

Expertise

GMP production of cell therapy products; design, validation and management of GMP
manufacturing facilities; regulatory compliance for cell therapy; immune
monitoring; T cell functional assays; dendritic cell (DC) biology; leukocyte
recruitment; liver immunology; cancer immunotherapy; cancer vaccines.

Other activities

In addition to his research work, Stuart plays an active role in public engagement for the Centre for Liver Research, taking part in laboratory tours, research showcase days, and patient and public involvement activities.  Stuart sits on the executive committee for the NIHR Liver Biomedical Research Unit and the scientific advisory board for CIIC.

Publications

Fletcher NF, Sutaria R, Jo J, Barnes A, Blahova M, Meredith LW, Cosset FL, Curbishley SM, Adams DH, Bertoletti A, McKeating JA. Activated macrophages promote hepatitis C virus entry in a tumor necrosis factor-dependent manner. Hepatology. 2014 Apr;59(4):1320-30

Liaskou E, Zimmermann HW, Li KK, Oo YH, Suresh S, Stamataki Z, Qureshi O, Lalor PF, Shaw J, Syn WK, Curbishley SM, Adams DH. Monocyte subsets in human liver disease show distinct phenotypic and functional characteristics. Hepatology. 2013 Jan;57(1):385-98.

Aspinall AI, Curbishley SM, Lalor PF, Weston CJ; Miroslava Blahova, Liaskou E, Adams RM, Holt AP, Adams DH. CX(3)CR1 and vascular adhesion protein-1-dependent recruitment of CD16(+) monocytes across human liver sinusoidal endothelium. Hepatology. 2010 Jun;51(6):2030-9.

Lalor PF, Curbishley SM, Adams DH. Identifying homing interactions in T-cell traffic in human disease. Methods Mol Biol. 2010;616:231-52.

Oo YH, Weston CJ, Lalor PF, Curbishley SM, Withers DR, Reynolds GM, Shetty S, Harki J, Shaw JC, Eksteen B, Hubscher SG, Walker LS, Adams DH. Distinct roles for CCR4 and CXCR3 in the recruitment and positioning of regulatory T cells in the inflamed human liver. J Immunol. 2010 Mar 15;184(6):2886-98.

Croudace JE, Curbishley SM, Mura M, Willcox CR, Illarionov PA, Besra GS, Adams DH, Lammas DA. Identification of distinct human invariant natural killer T-cell response phenotypes to alpha-galactosylceramide. BMC Immunol. 2008 Dec 3;9:71.

Adams DH, Eksteen B, Curbishley SM. Immunology of the gut and liver: a love/hate relationship. Gut. 2008 Jun;57(6):838-48.

Lai WK, Curbishley SM, Goddard S, Alabraba E, Shaw J, Youster J, McKeating J, Adams DH. Hepatitis C is associated with perturbation of intrahepatic myeloid and plasmacytoid dendritic cell function. J Hepatol. 2007 Sep;47(3):338-47.

Eksteen B, Miles A, Curbishley SM, Tselepis C, Grant AJ, Walker LS, Adams DH. Epithelial inflammation is associated with CCL28 production and the recruitment of regulatory T cells expressing CCR10. J Immunol. 2006 Jul 1;177(1):593-603.

Curbishley SM, Eksteen B, Gladue RP, Lalor P, Adams DH. CXCR 3 activation promotes lymphocyte transendothelial migration across human hepatic endothelium under fluid flow. Am J Pathol. 2005 Sep;167(3):887-99.